DK2781221T3 - Medicin til behandling og/eller forbedring af sepsis - Google Patents

Medicin til behandling og/eller forbedring af sepsis Download PDF

Info

Publication number
DK2781221T3
DK2781221T3 DK12850047.7T DK12850047T DK2781221T3 DK 2781221 T3 DK2781221 T3 DK 2781221T3 DK 12850047 T DK12850047 T DK 12850047T DK 2781221 T3 DK2781221 T3 DK 2781221T3
Authority
DK
Denmark
Prior art keywords
medication
treat
sepsis
improve sepsis
improve
Prior art date
Application number
DK12850047.7T
Other languages
English (en)
Inventor
Kazuhisa Tsuruta
Yoshikazu Aoki
Yutaka Osawa
Inder KAUL
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Application granted granted Critical
Publication of DK2781221T3 publication Critical patent/DK2781221T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK12850047.7T 2011-11-15 2012-11-14 Medicin til behandling og/eller forbedring af sepsis DK2781221T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559864P 2011-11-15 2011-11-15
PCT/JP2012/079449 WO2013073545A1 (ja) 2011-11-15 2012-11-14 敗血症の治療及び／又は改善のための医薬

Publications (1)

Publication Number Publication Date
DK2781221T3 true DK2781221T3 (da) 2020-06-02

Family

ID=48429601

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12850047.7T DK2781221T3 (da) 2011-11-15 2012-11-14 Medicin til behandling og/eller forbedring af sepsis

Country Status (18)

Country Link
US (5) US8772239B2 (da)
EP (1) EP2781221B9 (da)
JP (2) JP5902195B2 (da)
KR (1) KR101672108B1 (da)
CN (1) CN103974710B (da)
AU (1) AU2012337838B2 (da)
BR (1) BR112014011488B1 (da)
CA (1) CA2854882C (da)
DK (1) DK2781221T3 (da)
ES (1) ES2795439T3 (da)
HU (1) HUE050698T2 (da)
IL (1) IL232434B (da)
MX (1) MX354981B (da)
PL (1) PL2781221T3 (da)
PT (1) PT2781221T (da)
RU (1) RU2580756C2 (da)
WO (1) WO2013073545A1 (da)
ZA (1) ZA201403494B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2781221T3 (da) 2011-11-15 2020-06-02 Asahi Kasei Pharma Corp Medicin til behandling og/eller forbedring af sepsis
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
US9730983B2 (en) * 2015-10-02 2017-08-15 Chih-Yuan MA Methods for treatment of CD14-mediated disorders and responses
EP3971572A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2020067389A1 (ja) 2018-09-28 2020-04-02 旭化成ファーマ株式会社 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬
WO2020084853A1 (ja) 2018-10-22 2020-04-30 旭化成ファーマ株式会社 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005053A1 (fr) 1987-01-08 1988-07-14 Asahi Kasei Kogyo Kabushiki Kaisha Peptide servant a accelerer l'activation de la proteine c avec de la thrombine
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
EP0285511B1 (en) 1987-04-01 1992-11-25 Mitsubishi Gas Chemical Company, Inc. Immunoassay of thrombomodulin
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH0798840B2 (ja) 1988-12-27 1995-10-25 持田製薬株式会社 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物
US5202421A (en) 1988-12-27 1993-04-13 Mochida Pharmaceutical Co., Ltd. Anticoagulant substance obtained from urine and process for the preparation thereof
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
CA2022713A1 (en) 1989-08-11 1991-02-12 Nils U. Bang Human thrombomodulin derivatives
JPH03259084A (ja) 1990-03-06 1991-11-19 Kowa Co トロンビン結合性物質の製造法
AU643306B2 (en) 1990-06-27 1993-11-11 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
AU8723391A (en) 1990-08-15 1992-03-17 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
JP3220174B2 (ja) 1990-12-12 2001-10-22 第一製薬株式会社 組換ヒトトロンボモジュリン誘導体
CA2129370A1 (en) 1992-02-05 1993-08-19 David Richard Light Protease-resistant thrombomodulin analogs
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2003061687A1 (fr) 2002-01-18 2003-07-31 Asahi Kasei Pharma Corporation Preparation a concentration elevee de thrombomoduline soluble
US8293710B2 (en) 2005-01-03 2012-10-23 Blue Blood Biotech Corp. Method for treating wounds using an EGF-like domain of thrombomodulin
WO2008038777A1 (en) 2006-09-29 2008-04-03 Asahi Kasei Pharma Corporation Therapeutic agent for disseminated intravascular coagulation syndrome
US8076298B2 (en) 2006-12-12 2011-12-13 Eli Lilly And Company Treating acute renal failure with soluble thrombomodulin variants
ES2496596T3 (es) 2007-03-23 2014-09-19 Asahi Kasei Pharma Corporation Método para producir trombomodulina soluble de gran pureza
AR067345A1 (es) 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
US20110144024A1 (en) 2008-07-16 2011-06-16 Paion Deutschland Gmbh Prevention and treatment of radiation injury
DE202009007655U1 (de) 2009-05-29 2009-08-13 Design Ballendat Gmbh Kettenstuhl
DK2781221T3 (da) 2011-11-15 2020-06-02 Asahi Kasei Pharma Corp Medicin til behandling og/eller forbedring af sepsis
JP6441759B2 (ja) 2015-07-24 2018-12-19 株式会社堀場製作所 分光分析器に用いられる光検出器の出力補正方法

Also Published As

Publication number Publication date
AU2012337838B2 (en) 2016-04-21
US20140296148A1 (en) 2014-10-02
US20150157695A1 (en) 2015-06-11
ES2795439T3 (es) 2020-11-23
JP5902195B2 (ja) 2016-04-13
AU2012337838A1 (en) 2014-05-29
HUE050698T2 (hu) 2020-12-28
IL232434B (en) 2018-03-29
NZ624542A (en) 2015-06-26
US9034823B2 (en) 2015-05-19
MX2014005895A (es) 2014-06-19
KR101672108B1 (ko) 2016-11-02
BR112014011488A2 (pt) 2017-05-02
CA2854882A1 (en) 2013-05-23
US20160331813A1 (en) 2016-11-17
JPWO2013073545A1 (ja) 2015-04-02
MX354981B (es) 2018-03-28
EP2781221A4 (en) 2015-07-15
PL2781221T3 (pl) 2020-08-24
US8772239B2 (en) 2014-07-08
US9592275B2 (en) 2017-03-14
ZA201403494B (en) 2016-04-28
CN103974710A (zh) 2014-08-06
US20130244926A1 (en) 2013-09-19
RU2014124171A (ru) 2015-12-27
EP2781221B1 (en) 2020-04-08
BR112014011488B1 (pt) 2022-07-05
CN103974710B (zh) 2016-07-06
RU2580756C2 (ru) 2016-04-10
CA2854882C (en) 2016-03-29
EP2781221A1 (en) 2014-09-24
IL232434A0 (en) 2014-06-30
KR20140095559A (ko) 2014-08-01
US20130237482A1 (en) 2013-09-12
US9555080B2 (en) 2017-01-31
JP2016104803A (ja) 2016-06-09
EP2781221B9 (en) 2020-09-02
WO2013073545A1 (ja) 2013-05-23
HK1196289A1 (zh) 2014-12-12
PT2781221T (pt) 2020-06-01

Similar Documents

Publication Publication Date Title
IL262110A (en) Dll3 modulators and methods of use
IL230469A0 (en) Curable compositions and membranes
EP2724557A4 (en) PROVISION OF RELEVANT CONTENT
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
PL2613535T3 (pl) Sposób kodowania i dekodowania wideo
BR112014006324A2 (pt) método para tratar hcv
EP2761573A4 (en) PROCEDURE FOR ADMINISTRATION AND VIEW OF FOLLOWING CONTENT
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
PL3442228T3 (pl) Sposób dekodowania obrazów
BR112014010450A2 (pt) composição e método
EP2726969A4 (en) DISPLAY OF CONTENT
BR112013014644A2 (pt) composição farmacêutica e complexo
BR112013008068A2 (pt) método para reduzir o estresse hídrico em plantas
BR112014009785A2 (pt) método para tratar ou reduzir efp
DK3232663T3 (da) Fremgangsmåder og anordninger til afkodning
BRDI7106337S (pt) Configuração aplicada em mamadeira
BRDI7106333S (pt) Configuração aplicada em mamadeira
DK2670591T3 (da) Strukturelement og fremgangsmåde til dets fremstilling
BRDI7106341S (pt) Configuração aplicada em mamadeira
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
BR302012004766S1 (pt) Configuracao aplicada em injetor médico
BR112013022254A2 (pt) método e disposição para gerar oxigênio
BR112014010860A2 (pt) composição e método
DK2847570T3 (da) Reagens til klaring af emulsioner og fremgangsmåde til klaring